Pegcetacoplan for Complement 3 Glomerulopathy

(PRESERVE Trial)

This trial tests pegcetacoplan, a medicine that may prevent kidney problems from recurring after a transplant in individuals with specific kidney conditions. It focuses on two diseases: C3 glomerulopathy (C3G) and primary IC-MPGN, both of which can damage the kidneys. Suitable candidates for this trial include those with one of these conditions who are undergoing a kidney transplant and have either experienced recurring kidney issues or are at high risk of recurrence. Participants must also be fully vaccinated against certain infections, such as meningitis, according to local guidelines. As a Phase 3 trial, this represents the final step before FDA approval, offering participants access to a potentially groundbreaking treatment.

Research has shown that pegcetacoplan is generally safe for individuals with certain kidney conditions. Previous studies found it to be safe, with no serious side effects reported even after long-term use. Most side effects were mild to moderate, indicating they weren't severe. Importantly, no participants discontinued the treatment due to side effects, and no deaths were related to the treatment. This suggests that many patients can tolerate pegcetacoplan well.¹²³⁴⁵

Unlike the standard treatments for Complement 3 Glomerulopathy (C3G), which often include general immunosuppressants, Pegcetacoplan specifically targets the complement system, a part of the immune system involved in this disease. Pegcetacoplan is a complement C3/C3b inhibitor, which means it directly interferes with the part of the immune response that contributes to kidney damage in C3G. Researchers are excited because this targeted approach could potentially reduce kidney damage more effectively and with fewer side effects than traditional treatments.

Research has shown that pegcetacoplan, the treatment under study in this trial, can help treat C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). One study found that pegcetacoplan reduced protein in urine by 68%, a key indicator of kidney damage. The treatment also maintained stable kidney function over time. In everyday use, patients experienced an 81% reduction in urine protein within six months. This suggests that pegcetacoplan protects kidney function by lowering harmful substances in the blood. No kidney transplant patients experienced graft loss or rejection during treatment, indicating its safety.²⁵⁶⁷⁸